NR4A1 and breast carcinoma: The combination of CDK4/6 inhibitors (CDK4/6i) with endocrine therapy (ET) has been approved by the FDA as a first-line treatment regimen for patients with advanced hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer [15].